Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 15, 2021, our Board of Directors appointed John Driscoll to serve as a
member of the Board of Directors and as our new Chief Financial Officer.
John Driscoll, age 54, is our new Chief Financial Officer and a new member of
our Board of Directors. Mr. Driscoll is an experienced finance executive with 30
years of expertise as a Chief Audit Executive heading large-scale audit
engagements for FinTech, banking, manufacturing and insurance companies. He
transitioned through three corporate M&A's heading global audit operations and
facilitating changes to the global organizational chart and corporate culture
mission statement. Mr. Driscoll has reported to boards, audit committees, and
top management teams to objectively review and report on findings that impact
operational, financial, and compliance controls spanning the global enterprise.
He provides recommendations, insights, and the tools needed to attain goals,
mitigate risks, and meet stakeholder expectations. Mr. Driscoll's professional
experience includes:
· NY County District Attorney, Supervisor Forensic Accountant - January
1990-November 1997
· AIG, Senior Auditor, Internal Audit - December 1997- May 2000
· Philip Morris, Director, Internal Audit - June 2000-November 2000
· AIG, Supervisor, Internal Audit - December 2000-July 2010
· CIT, Vice President, Internal Audit - August 2010-July 2014
· Fundtech, Vice President, Head of Global Audit - August 2014-June
2015
· D&H, Chief Audit Executive - July 2015-July 2017
· Finastra, Chief Audit Executive - August 2017-December 2019
· ST Brands/Biosciences-EVP, Chief Financial Officer - January
2020-June 2021
Mr. Driscoll holds an M.S. in Management from Utica College and a B.S. in
Finance from St. John's University.
Mr. Driscoll has no family relationships with any of the Company's directors or
executive officers. Mr. Driscoll is currently the Chief Financial Officer of ST
Biosciences, a subsidiary of ST Brands, Inc. As disclosed in our Current Report
on Form 8-K filed May 7, 2021, we acquired ST Brands, Inc. under an Exchange
Agreement dated May 3, 2021. Mr. Driscoll has not had any other direct or
indirect material interest in any transaction required to be disclosed pursuant
to Item 404(a) of Regulation S-K. Compensation arrangements for Mr. Driscoll
have not been determined at this time.
© Edgar Online, source Glimpses